Overview of the 3 trials and patients included in the analysis
| . | CLL2-BIO . | CLL2-BIG . | CLL2-BAG . | Total . |
|---|---|---|---|---|
| Evaluable patients | 65 | 61 | 63 | 189 |
| ORR at end of induction, % | 92 | 100 | 95 | NA |
| uMRD level (<10−4) at end of induction, % | 14 | 48 | 87 | NA |
| Data cutoff | 14 October 2020 | 20 May 2019 | 17 February 2021 | NA |
| Observation time, median (range), mo | 38 (8-43) | 38 (5-49) | 38 (8-56) | 38 (5-56) |
| Patients with del(17p)/TP53 mutation | 21 | 13 | 17 | 51 |
| Observation time, median (range), mo | 45 (8-55) | 41 (21-67) | 61 (8-68) | 49 (8-68) |
| . | CLL2-BIO . | CLL2-BIG . | CLL2-BAG . | Total . |
|---|---|---|---|---|
| Evaluable patients | 65 | 61 | 63 | 189 |
| ORR at end of induction, % | 92 | 100 | 95 | NA |
| uMRD level (<10−4) at end of induction, % | 14 | 48 | 87 | NA |
| Data cutoff | 14 October 2020 | 20 May 2019 | 17 February 2021 | NA |
| Observation time, median (range), mo | 38 (8-43) | 38 (5-49) | 38 (8-56) | 38 (5-56) |
| Patients with del(17p)/TP53 mutation | 21 | 13 | 17 | 51 |
| Observation time, median (range), mo | 45 (8-55) | 41 (21-67) | 61 (8-68) | 49 (8-68) |
NA, not applicable